glp-1 and seizures LY3437943, a novel triple glucagon, GIP, receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Repurposing glucagon-like peptide-1 receptor agonists

Understanding how these medications interact with your digestive system helps you anticipate potential side effects and recognize when symptoms require medical attention

Increased Co-Expression of PSMA2 and GLP-1 Receptor in Cervical Cancer Models in Type 2 Diabetes Attenuated by Exendin-4: A Translational Case-Control Study

Glitazones Glitazones are metabolised in the liver and less than 2% is eliminated in urine

So my first question is for you, Cory, you are our government affairs lead the global Healthy Living Foundation

Landmark studies such as LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) have shown significant reductions in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors